Modera Wealth Management LLC Sells 197 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Modera Wealth Management LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,299 shares of the medical equipment provider’s stock after selling 197 shares during the period. Modera Wealth Management LLC’s holdings in Zimmer Biomet were worth $771,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the last quarter. Van ECK Associates Corp lifted its stake in Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares during the last quarter. Hotchkis & Wiley Capital Management LLC lifted its stake in Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Equity Investment Corp increased its position in shares of Zimmer Biomet by 57.2% in the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after acquiring an additional 371,653 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Zimmer Biomet by 0.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider’s stock valued at $108,621,000 after acquiring an additional 4,388 shares during the period. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ZBH. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial reiterated a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Down 1.3 %

Shares of Zimmer Biomet stock opened at $103.98 on Wednesday. The company has a market cap of $20.70 billion, a price-to-earnings ratio of 23.37, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company’s 50 day moving average is $105.63 and its 200 day moving average is $107.28. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business earned $2.20 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.